Search research articles
Contact Us
Filters
Showing results (111-120 of 147) with videos related to
Page
of 15
Sort By:
Journal of Personalized Medicine
|
October 27, 2022
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
Kenneth Blum, Catherine A Dennen, Igor Elman, et al.
Journal of Personalized Medicine
|
December 23, 2022
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
Edward Justin Modestino, Kenneth Blum, Catherine A Dennen, et al.
Journal of Personalized Medicine
|
December 24, 2025
Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) Axis
Alireza Sharafshah, Kenneth Blum, Kai-Uwe Lewandrowski, et al.
Neuroimage
|
November 29, 2011
Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine
Jaymin Upadhyay, Julie Anderson, Richard Baumgartner, et al.
Journal of Personalized Medicine
|
December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
Mauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of the Neurological Sciences
|
September 9, 2022
Why haven't we solved the addiction crisis?
Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Journal of Personalized Medicine
|
September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects
Kenneth Blum, David Han, Ashim Gupta, et al.
Journal of Personalized Medicine
|
December 29, 2022
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index
Kenneth Blum, David Han, Abdalla Bowirrat, et al.
Journal of Personalized Medicine
|
February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?
Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
Journal of Personalized Medicine
|
June 24, 2022
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
Kenneth Blum, Mark S Brodie, Subhash C Pandey, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 147) with videos related to
Sort By:
Page
of 15
Journal of Personalized Medicine
|
October 27, 2022
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
Kenneth Blum, Catherine A Dennen, Igor Elman, et al.
Journal of Personalized Medicine
|
December 23, 2022
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
Edward Justin Modestino, Kenneth Blum, Catherine A Dennen, et al.
Journal of Personalized Medicine
|
December 24, 2025
Pharmacoepigenomics in Personalized Medicine: A Hypothesis-Generating Approach to Introduce CpG-PGx SNPs as New Candidates for a Systematic Insight into Genomic-Epigenomic-Phenomic-Pharmacogenomics (G-E-Ph-PGx) Axis
Alireza Sharafshah, Kenneth Blum, Kai-Uwe Lewandrowski, et al.
Neuroimage
|
November 29, 2011
Modulation of CNS pain circuitry by intravenous and sublingual doses of buprenorphine
Jaymin Upadhyay, Julie Anderson, Richard Baumgartner, et al.
Journal of Personalized Medicine
|
December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
Mauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.
Journal of the Neurological Sciences
|
September 9, 2022
Why haven't we solved the addiction crisis?
Kenneth Blum, Abdalla Bowirrat, Luis Llanos Gomez, et al.
Journal of Personalized Medicine
|
September 23, 2022
Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case-Control Subjects
Kenneth Blum, David Han, Ashim Gupta, et al.
Journal of Personalized Medicine
|
December 29, 2022
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index
Kenneth Blum, David Han, Abdalla Bowirrat, et al.
Journal of Personalized Medicine
|
February 25, 2022
Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It "Blowin' in the Wind"?
Kenneth Blum, Thomas McLaughlin, Abdalla Bowirrat, et al.
Journal of Personalized Medicine
|
June 24, 2022
Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
Kenneth Blum, Mark S Brodie, Subhash C Pandey, et al.
Page
of 15